These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2634542)

  • 41. Induction of antitumor activity and experimental expansion of human lung cancer-infiltrating lymphocytes.
    Xu Z; Shao J; Zhang Y; Li D; Li Y; Ba D
    Chin Med Sci J; 1991 Jun; 6(2):87-91. PubMed ID: 1804382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma.
    Handgretinger R; Bruchelt G; Kimmig A; Dopfer R; Niethammer D; Treuner J
    Pediatr Hematol Oncol; 1989; 6(4):307-17. PubMed ID: 2641703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.
    Monson JR; Ramsden CW; Giles GR; Brennan TG; Guillou PJ
    Gut; 1987 Nov; 28(11):1420-5. PubMed ID: 3501386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-tumor effect of human lymphocytes and interleukin-2.
    Anwer F; Mesri M; Rees RC; Kazmi SU
    J Pak Med Assoc; 1993 Mar; 43(3):45-9. PubMed ID: 8326667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction and expansion of LAK cells for cancer immunotherapy.
    Hamblin TJ
    Prog Clin Biol Res; 1990; 337():551-3. PubMed ID: 2353017
    [No Abstract]   [Full Text] [Related]  

  • 49. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
    Rosenberg SA; Spiess P; Lafreniere R
    Science; 1986 Sep; 233(4770):1318-21. PubMed ID: 3489291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
    Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
    Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma.
    Burger RA; Grosen EA; Ioli GR; Van Eden ME; Park M; Berman ML; Manetta A; Disaia PJ; Granger GA; Gatanaga T
    J Interferon Cytokine Res; 1995 Mar; 15(3):255-60. PubMed ID: 7584672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients.
    Hess AD; Gall SA; Dawson JR
    Cancer Res; 1979 Jul; 39(7 Pt 1):2381-9. PubMed ID: 36225
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells.
    Allavena P; Pirovano P; Bonazzi C; Colombo N; Mantovani A; D'Incalci M
    J Natl Cancer Inst; 1990 Jan; 82(2):139-42. PubMed ID: 2294223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of anti-CD3 monoclonal antibody OKT3 on LAK cells generated from TIL of colorectal cancer: preliminary report].
    Ohta T; Kikuch H; Tomizawa H; Ogata H; Yoshida K; Watanabe H
    Nihon Geka Gakkai Zasshi; 1990 Jun; 91(6):788. PubMed ID: 2398873
    [No Abstract]   [Full Text] [Related]  

  • 55. Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells.
    Haskill S; Koren H; Becker S; Fowler W; Walton L
    Br J Cancer; 1982 May; 45(5):737-46. PubMed ID: 6177328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppression of natural killer activity by ascitic fluid from patients with gastrointestinal cancer.
    Fujimoto S; Amemiya K; Ishigami H; Shimura T; Okui K
    Nihon Gan Chiryo Gakkai Shi; 1984 May; 19(4):789-95. PubMed ID: 6593385
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunosuppressive effects of peritoneal fluids from ovarian cancer patients.
    Onsrud M
    Gynecol Oncol; 1986 Mar; 23(3):316-22. PubMed ID: 3957117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of natural cell-mediated resistance in human solid tumors.
    Allavena P; Merendino A; Di Bello M; Pirelli A; Rossini S; Mantovani A
    Biochim Biophys Acta; 1986 Dec; 865(3):281-8. PubMed ID: 2431716
    [No Abstract]   [Full Text] [Related]  

  • 59. Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.
    Sheid B; Boyce J
    Cancer Immunol Immunother; 1984; 17(3):190-4. PubMed ID: 6332671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.
    Kradin RL; Boyle LA; Preffer FI; Callahan RJ; Barlai-Kovach M; Strauss HW; Dubinett S; Kurnick JT
    Cancer Immunol Immunother; 1987; 24(1):76-85. PubMed ID: 3493073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.